Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03671785 · ClinicalTrials.gov registry record · Phase 1
Study of the Fecal Microbiome in Patients With Parkinson's Disease
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03671785 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 15 participants.
The verdict
NCT03671785, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the intestinal microbiome in subjects with Parkinson's disease and to determine safety and trends in improvements in diversity of colonic microbiome following administration of lyophilized PRIM-DJ2727
Interventions
- DRUG PRIM-DJ2727
- DRUG Placebo oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2022-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03671785
The ClinicalTrials.gov registry entry for NCT03671785 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PRIM-DJ2727 is the first listed.
NCT03671785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03671785 about?
NCT03671785 is a clinical study titled "Study of the Fecal Microbiome in Patients With Parkinson's Disease". The purpose of this study is to characterize the intestinal microbiome in subjects with Parkinson's disease and to determine safety and trends in improvements in diversity of colonic microbiome following administration of lyophilized PRIM-DJ2727
What is the current status of trial NCT03671785?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-05-15. Estimated completion is 2022-10-12.
What interventions are being tested in trial NCT03671785?
The interventions under investigation include: PRIM-DJ2727 (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT03671785?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.